Key ELN 2022 rules
- FLT3-ITD is no longer split by allelic ratio; NPM1 with FLT3-ITD is intermediate [1].
- Only in-frame bZIP mutations of CEBPA are favourable (mono- or biallelic) [1].
- Mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1 and ZRSR2 are adverse unless they occur with favourable subtypes [1].
- NPM1 with adverse cytogenetics is adverse [1].
- The classification applies to intensive treatment; after treatment, MRD refines prognosis [1].
Treatment details: AML and ELN 2022 lesson.
Related cancer types
Treatment regimens (physicians)
Physician tools and lessons
Cumulative Anthracycline Dose and Doxorubicin EquivalentsTumour Lysis Syndrome: Cairo-Bishop Criteria and PreventionHCT-CI Comorbidity Index Before Stem Cell TransplantationCLL-IPI Calculator (Chronic Lymphocytic Leukaemia Prognostic Index)ELTS and Sokal Score Calculator in Chronic Myeloid Leukaemia (CML)IPSS-R Calculator for Myelodysplastic Syndromes (MDS)Indications for haematopoietic stem cell transplantation, donor selection and conditioningGraft-versus-host disease (GVHD): prophylaxis, grading and treatment10 cheap steps that save patients' livesAcute myeloid leukaemia (AML): 2022 classification, ELN genetic risk and treatment
References
1 referenceShow all references, 1 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/eln-2022-aml-risk/